LA
DMRA

Lee Ainslie’s Damora Therapeutics DMRA Stock Holding History

Lee Ainslie’s Portfolio DMRA Stock Details DMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-14,252
Closed -$1.8M – 702
2021
Q2 		$1.8M Sell
14,252
-5,055
-26% -$689K 0.02% 181
2021
Q1 		$2.9M Sell
19,307
-311
-2% -$84.6K 0.03% 115
2020
Q4 		$5.85M Buy
+19,618
New +$7.3M 0.09% 57

Other funds holding DMRA

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $5.69B AUM 60.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Lee Ainslie's DMRA Position: Q3 2021 in Review

Lee Ainslie sold out of Damora Therapeutics (DMRA) in Q3 2021, closing a stake of 14,252 shares — an estimated $1.8M sold.

Lee Ainslie first reported a position in DMRA in Q4 2020 and held it in 3 quarters. The position peaked at $5.85M in Q4 2020. 25 funds tracked by Wall St. Rank hold DMRA as of Q3 2021.

  • Lee Ainslie reported no remaining Damora Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Lee Ainslie sold 14,252 Damora Therapeutics shares in Q3 2021, an estimated $1.8M.
  • Lee Ainslie first reported a position in Damora Therapeutics in Q4 2020 and held it in 3 quarters.
  • Lee Ainslie's Damora Therapeutics position peaked at $5.85M in Q4 2020.
  • 25 funds tracked by Wall St. Rank held Damora Therapeutics as of Q3 2021.

Based on Maverick Capital's 13F filing for Q3 2021, filed 15 Nov 2021.